AIDD-Ready Core Product Portfolio
Essential Resources for AI Drug Screening & Validation
- Affinity-Validated Target Proteins
- Challenging-Target Proteins & Functional Cell Lines IP Friendly
- TR-FRET Solutions
Faced with the large number of antibody candidates generated by AI, efficient screening requires reliable, ready-to-use antigens. ACRO offers recombinant proteins covering a broad range of drug targets. Validated by BLI/SPR affinity testing, these proteins can be used directly for binding and affinity screening of antibody candidates, enabling rapid Hit identification while reducing time spent on protein preparation and assay optimization—well suited to the high-throughput, fast-paced nature of AI-driven drug development.
AIDD-Ready Core Service Platform:
CHO-Direct™
CHO-Direct™ is purpose-built for AI-driven antibody pipelines, connecting the full workflow from AI-powered design → Stage 1: high-throughput screening → Stage 2: antibody expression & purification → Stage 3: in-depth characterization → AI model iteration / preclinical development. It provides a standardized, reproducible, and iterative wet-lab framework to efficiently advance AI-designed antibodies from virtual design to preclinical development.
AIDD-Ready also includes a cell-free expression (CFS) platform for rapid production of small proteins such as VHHs and mini-proteins. With fast turnaround, CFS complements CHO-Direct™ to support wet-lab validation across diverse AI-designed molecules.
- Stage 1: High-Throughput Screening
- Stage 2: Antibody Expression & Purification
- Stage 3: In-Depth Characterization
Stage 1: High-Throughput Supernatant Screening (Rapid Candidate Screening & Model Iteration)
High-throughput validation of AI-generated antibody sequences enables rapid identification of positive candidates and efficient elimination of non-performing sequences. This reduces downstream validation costs while generating the first round of experimental data to drive AI model iteration.
Standard Workflow
Automated Report Delivered in as Fast as 4 Days - Day 0
AI Antibody Sequence Receipt & Analysis
- Day 1
Gene Synthesis & Construct Generation
- Day 2
CHO Cell Transfection & Expression
- Day 3
Supernatant Harvest & Testing
- Day 4
Automated Report Delivery
Core Services
Standard Deliverables
Antibody Expression QuantificationAssess antibody expression to rapidly identify low-expressing or abnormal sequences
- BLI Affinity Ranking
High-throughput affinity analysis with automated reporting for efficient candidate ranking
Optional Assays- ELISA Binding Validation
Confirm binding specificity and minimize false positives
- Flow Cytometry Screening
Cell-based binding screening for membrane protein targets
- sELISA Epitope Binning
Characterize antibody epitopes
- Early Functional Assessment
TR-FRET/ELISA blocking and binding assays for early assessment of candidate activity
Core Service AdvantagesCHO-Direct™ Platform Equipment Showcase
CHO-Direct™ One-Stop Antibody Screening & Validation Service
Starting from AI-designed antibody sequences, CHO-Direct™ provides one-stop wet-lab validation covering high-throughput expression, functional activity, and developability assessment.